ClinicalTrials.gg
RecruitingNCT06323538COPLANTUpdated Feb 14, 2025

Cohort Study on Plant-based Diets (COPLANT Study)

An observational study in Dietary Exposure, Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by German Federal Institute for Risk Assessment. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by German Federal Institute for Risk Assessment · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.

Planned enrollment
16th of 66
6,000 · median 1,552
Started
2024
with 19 others
Observational
66 of 756
13 open now
Primary completion
2027-03
later than 22 of 66 live
Registered
695th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 16th largest by planned enrollment of the 66 observational ones that give a count, is one of 20 that started in 2024, is one of 66 observational ones, reaches primary completion later than 22 of the 66 other live ones, and was the 695th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, or all of them as a file.
02

Study summary

The Cohort on Plant-based Diets (COPLANT) study is a multi-centre cohort study that starts baseline recruitment from 2024 to 2027 with approximately 6,000 participants in Germany and Austria. The COPLANT study focuses on vegan (no animal products), vegetarian (no meat and fish, but dairy products and eggs), pescetarian (no meat, but fish) and omnivorous (mixed diet including all possible animal products) diets. The aim of the COPLANT study is to gain new insights on health benefits and risks as well as social, ecological and economic effects of different plant-based diets in comparison to a mixed diet. In addition to a detailed dietary survey using an app adapted to the needs of this study, the baseline examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants. Furthermore, specific aspects of dietary behavior, physical activity and other lifestyle factors are collected via questionnaires. Follow-up studies are planned at intervals of 5, 10 and 20 years after the baseline visit.

Read the detailed description

The multicenter Cohort on Plant-based diets (COPLANT) study, aims to investigate the health benefits as well as short-term and long-term risks of different plant-based diets (vegan: no animal products, vegetarian: no meat and fish, but dairy products and eggs, pescetarian: no meat, but fish) compared to a mixed diet among 6,000 participants aged 18 to 69 years across German speaking countries. Currently the impact of different diets not only on health effects, but also on social, ecological and economic factors is becoming increasingly evident in areas of social justice, climate change and animal welfare. For this reason, a sustainability analysis (social, ecological and economic effects) together with findings on health effects will be included in the COPLANT study. As plant-based diets, especially vegan diets, are associated with specific risks and benefits for certain population groups such as pregnant women, breastfeeding mothers and children, COPLANT will also establish appropriate research structures for these groups and include them in the study.

The detailed consumption survey of all study participants is one of the main pillars of the planned study. Of particular importance is the dietary assessment of novel vegan and vegetarian foods, thus an app adapted to the needs of this study was developed. The characterisation of external and internal intakes of nutrients and contaminants within a particular diet will be examined. Large epidemiological projects currently underway in Germany, such as the NAKO Health Study, are unable to answer these questions. In order to prospectively investigate links between diet and the later occurrence of common diseases such as type 2 diabetes, cardiovascular diseases and cancer, the study participants should be followed up for at least 20 years if third-party funding is successfully acquired.

The study is to be conducted in study centers at the Federal Institute for Risk Assessment (BfR), Berlin, the Max Rubner-Institut (MRI) in Karlsruhe, the Rheinische Friedrich-Wilhelms University in Bonn, the Friedrich Schiller University Jena, the Research Institute for Plant-Based Nutrition in Giessen, in cooperation with the Justus Liebig University Giessen and at the universities of Heidelberg, Regensburg and Vienna. Furthermore, the basic examination includes measurements of body composition, bone health, cardiovascular risk factors, diabetes risk, contaminants and lifestyle. Specific aspects of dietary behavior, physical activity and other lifestyle factors will be assessed using questionnaires. For the basic laboratory program, fasting blood, 24-hour urine collection and a stool sample are taken from all study participants.

Participants will be recruited for the baseline study from 2024 to 2027. Follow-up visits are planned at intervals of 5, 10 and 20 years.

03

Conditions studied

  • Dietary Exposure
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • Bone Loss
  • Sustainability
  • Exposure
  • Obesity
  • Vitamin Deficiency
  • Mineral Deficiency

Keywords

  • vegan
  • vegetarian
  • pescetarian
  • omnivor
  • multicenter cohort
  • biomarker
  • vitamins
  • minerals
  • bone health
  • cardiovascular risk
  • body composition
  • inflammation
  • contaminants
  • diabetes type 2
  • thyroid gland health
  • microbiota
  • metabolomics
  • adults
  • children
  • pregnancy
  • breast feeding time
  • mental health
  • sustainability
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Vegans - no consumption of animal products (less than one exception per month)

Vegetarians

  • no consumption of meat and fish (less than one exception per month)
  • consumption of eggs and/or dairy products (at least once a month)

Pescetarians

  • no consumption of meat (less than one exception per month)
  • consumption of fish (at least once a month)
  • consumption of eggs or dairy products possible

Omnivores/ mixed diet - group of non-exposed persons or control group

  • consumption of meat or sausage (at least once a month).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 18 and 69 years at recruitment (age-stratified recruitment in four age groups (18 to 29, 30 to 39, 40 to 49 and 50 to 69 years) which should be equally distributed across the four diets)
  • following their current diet for at least one year
  • health insured
  • are willing to have blood taken (adults)
  • are willing and able to complete questionnaires
  • only at Berlin, Jena, Giessen and Karlsruhe sites: pregnant and breastfeeding women were recruited (shortened examination programm)
  • only at the Regensburg, Heidelberg, Bonn and Vienna sites: are neither pregnant nor breastfeeding at the time of recruitment
  • only at Berlin and Karlsruhe sites: children of adult participants (shortened examination programm without collection of blood, urine, and stool)
  • are able to give to participate in the study
  • have given their consent to participate in the COPLANT study

Exclusion criteria

Exclusion Criteria:

  • who can no longer be contacted
  • who withdraw their consent to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • vegans

    vegan diet: no products of animal origin

  • vegetarians

    vegetarian diet: no meat and fish, but dairy products and eggs

  • pescetarians

    pescetarian diet: no meat, but fish

  • mixed diet

    mixed diet: plant-based foods and animal-based foods

06

What researchers measure

Primary outcomes

  1. Incidence of diabetes type 2

    Incidence of diabetes type 2

    Time frame: 5, 10, 20 years

Secondary outcomes

  1. Incidence of cardiovascular diseases

    Incidence of cardiovascular diseases

    Time frame: 10, 20 years

  2. Incidence of cancer

    Incidence of cancer

    Time frame: 10, 20 years

  3. Vitamin B12

    Vitamin B12 (pmol/l)

    Time frame: Baseline

  4. Holo-transcobalamine

    Holo-transcobalamine (pmol/l),

    Time frame: Baseline

  5. Homocysteine

    Homocysteine (µmol/l)

    Time frame: Baseline

  6. Methylmalonic acid

    Methylmalonic acid (µg/l)

    Time frame: Baseline

  7. Vitamin B1 status

    Vitamin B1 (nmol/l)

    Time frame: Baseline

  8. Vitamin B2 status

    Vitamin B2 (µg/l)

    Time frame: Baseline

  9. Vitamin B6 status

    Vitamin B6 (nmol/l)

    Time frame: Baseline

  10. Vitamin C status

    Vitamin C (mg/l)

    Time frame: Baseline

  11. Vitamin D status

    Vitamin D (nmol/l)

    Time frame: Baseline

  12. Vitamin E status

    Vitamin E (µmol/l)

    Time frame: Baseline

  13. Iron

    Iron (µmol/l)

    Time frame: Baseline

  14. Ferritin

    Ferritin (µg/l)

    Time frame: Baseline

  15. Transferrin

    Transferrin (mg/dl)

    Time frame: Baseline

  16. Zinc status

    Zinc (µg/l)

    Time frame: Baseline

  17. Selenium status

    Selenium (µg/l)

    Time frame: Baseline

  18. Iodine status

    Iodine (µg/l)

    Time frame: Baseline

  19. Blood pressure

    Systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg)

    Time frame: Baseline

  20. Blood lipids

    Total cholesterol, LDL, HDL, triacylglycerides (mmol/l)

    Time frame: Baseline

  21. Fasting insulin

    Fasting insulin (mU/l)

    Time frame: Baseline

  22. Fasting glucose

    Fasting glucose (mmol/l)

    Time frame: Baseline

  23. Glycated hemoglobin (HbA1c)

    HbA1c (%)

    Time frame: Baseline

  24. C-peptide

    C-peptide (ng/ml)

    Time frame: Baseline

  25. Osteocalcin

    Osteocalcin (ng/ml)

    Time frame: Baseline

  26. Ostase

    Ostase (µg/l)

    Time frame: Baseline

  27. Parathormone

    Parathormone (ng/l)

    Time frame: Baseline

  28. N-terminal propeptide of type I procollagen (PINP)

    PINP (ng/ml)

    Time frame: Baseline

  29. C-terminal telopeptide of type I collagen (CTX)

    CTX (ng/ml)

    Time frame: Baseline

  30. Creatinine

    Creatinine (mmol/24h)

    Time frame: Baseline

  31. Uric acid

    Uric acid (mg/24h)

    Time frame: Baseline

  32. Cytstatin C

    Cytstatin C (mg/l)

    Time frame: Baseline

  33. Thyroid stimulating hormone (TSH)

    TSH (mU/l)

    Time frame: Baseline

  34. Free triiodothyronine (fT3)

    fT3 (pmol/l)

    Time frame: Baseline

  35. Free thyroxine (fT4)

    fT4 (pmol/l)

    Time frame: Baseline

  36. Body fat

    Body fat (kg)

    Time frame: Baseline

  37. Skeletal muscle mass

    Skeletal muscle mass (kg)

    Time frame: Baseline

  38. Total Body Water

    Total Body Water (l)

    Time frame: Baseline

  39. Energy intake

    Calories per day

    Time frame: Baseline

  40. Nutrient intake

    Milligramm per day

    Time frame: Baseline

  41. Intake of dietary supplements

    Frequencies per day

    Time frame: Baseline

  42. Intake of medication

    Frequencies per day

    Time frame: Baseline

Other outcomes

  1. Heavy metals

    Arsenic, lead, cadmium (µg/l)

    Time frame: Baseline

  2. Halogenated, polycyclic aromatic hydrocarbons (dioxins)

    Dioxins (ng/g lipid)

    Time frame: Baseline

  3. Mycotoxins

    Mycotoxins (ng/ml)

    Time frame: Baseline

  4. Per- and polyfluoroalkyl substances (PFAS)

    PFAS (ng/ml)

    Time frame: Baseline

  5. Microbiome

    16S rRNA sequencing

    Time frame: Baseline

07

Study locations

6 of 8 sites recruiting
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — In accordance with the informed consent of the COPLANT participants, pseudonymised study data could be provided to external researchers upon request for cooperation or data-use purposes. In this case, a cooperation or data use agreement must be concluded in advance. The use of COPLANT study data is therefore only possible with a detailed prior justification of its scientific purpose and after agreement of the steering commitee of the COPLANT study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 35 months is close to that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 21, 2024
StartActual
Apr 9, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2047
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06323538
Lead sponsor
German Federal Institute for Risk Assessment
Collaborators
Max Rubner-Institut, University of Bonn, Research Institute for Plant-Based Nutrition, University of Jena, University of Regensburg, Heidelberg University, University of Vienna
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Apr 9, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2047 (estimated)
Last update
Feb 14, 2025

Study contacts

Cornelia Weikert, Prof
Contact
Cornelia.Weikert@bfr.bund.de
+49 30 184155000
Christine Dawczynski, PhD
Contact
christine.dawczynski@uni-jena.de
+49 3641 949656
Ute Nöthlings, Prof
principal investigator · University Bonn
Christine Dawczynski, PhD
principal investigator · University Jena
Markus Keller, PhD
principal investigator · Research Institute for Plant-based Nutrition (IFPE)
Michael Leitzmann, Prof
principal investigator · University Regensburg
Ina Danquah, Prof
principal investigator · University Heidelberg
Maria Wakolbinger, Prof
principal investigator · University Vienna
Tilman Kühn, Prof
principal investigator · University Vienna
Beate Fischer, PhD
principal investigator · University Regensburg
Benedikt Merz, PhD
principal investigator · Max Rubner-Institut
Cornelia Weikert, Prof
principal investigator · Federal Institut for Risk Assessment

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion